THOMAS GRANT: Open Payments
NPI 1316587207 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$630 in 14 payments from 7 companies in 2025. Trend: 2023 $216 · 2024 $1,050 · 2025 $630
Food & beverage: $630
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 1 | $174 |
| Otsuka America Pharmaceutical, Inc. | 1 | $123 |
| Alkermes, Inc. | 4 | $112 |
| Janssen Pharmaceuticals, Inc | 2 | $94 |
| ABBVIE INC. | 3 | $65 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
Products named: INGREZZA, ABILIFY MAINTENA, ARISTADA, INVEGA SUSTENNA, VRAYLAR, UZEDY, AUSTEDO XR, CAPLYTA.
Industry payments across NY — which companies pay providers there.
